Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,088.93
(
-0.28%
)
US TECH 100
25,863.60
(
-0.03%
)
Dow Jones
49,282.88
(
-0.33%
)
Brent Oil
93.41
(
3.01%
)
Bitcoin
75,758.77
(
-0.18%
)
News Focus
News Focus
Post# of 822258
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

flipper44

Send PM Follow Ignore
Followers 308
Posts 37295
Boards Moderated 1
Alias Born 11/14/2013

flipper44

Member Level

Re: The Danish Dude post# 451992

Wednesday, 03/16/2022 2:01:31 PM

Wednesday, March 16, 2022 2:01:31 PM

Post# of 822258
Not certain that advancement applies to what you are arguing regarding Direct (potential) approval speed. They are tangentially related, but the primary relationship for Direct will be efficacy in its own right (as opposed to proving biosimilarity to DCVax-l)

On the other hand, DCVax-l automated (potential) manufacturing certification could be sped up by proving biosimilarity to manual product without the encumbrance of human/animal bridge efficacy studies.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News